The efficacy of nimodipine, a calcium channel blocker, has been tested in randomized controlled trials for the treatment of dementia, particularly Alzheimer's disease and multi-infarct dementia, the commonest forms of dementia in older people. The rationale for its use is to restrict the influx of calcium ions into neurons, and, by vasodilatation, to improve blood flow to the brain. This review found evidence of some short-term benefit attributable to nimodipine, mainly in measures of cognitive function and global impression, but not in activities on daily living, for patients with degenerative and multi-infarct dementia, and mixed dementia. Nimodipine is well tolerated with a low rate of adverse effects similar to that associated with placebo.
Evidence of some short-term benefit of nimodipine for people with dementia
7 July 2010
This record should be cited as:
Birks J, López-Arrieta J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000147. DOI: 10.1002/14651858.CD000147
Assessed as up to date:
25 May 2010
More like this
- Galantamine improves global and cognitive symptoms at doses of 16 mg/day or greater, in people with mild to moderate Alzheimer's disease, for at least 6 months
- No evidence of the efficacy of nicotine for Alzheimer's disease
- No evidence from randomised controlled trials for or against the use of Zhiling concoction in the treatment of people with vascular dementia
- There is no evidence from randomised controlled trials for or against the use of 'Yizhi capsule' as a treatment for vascular dementia
- There is currently no high quality evidence to support the use of Huperzine A for the treatment of vascular dementia.